滞后
医药制造业
连续生产
制造工程
制药工业
新产品开发
产品(数学)
质量保证
质量(理念)
先进制造业
良好制造规范
药物
过程开发
计算机科学
过程(计算)
制造工艺
工艺工程
业务
工程类
运营管理
药品
医学
材料科学
供应链
药理学
几何学
数学
环境工程
外部质量评估
营销
复合材料
病理
哲学
操作系统
认识论
作者
Christopher L. Burcham,Alastair J. Florence,Martin D. Johnson
标识
DOI:10.1146/annurev-chembioeng-060817-084355
摘要
The pharmaceutical industry has found new applications for the use of continuous processing for the manufacture of new therapies currently in development. The transformation has been encouraged by regulatory bodies as well as driven by cost reduction, decreased development cycles, access to new chemistries not practical in batch, improved safety, flexible manufacturing platforms, and improved product quality assurance. The transformation from batch to continuous manufacturing processing is the focus of this review. The review is limited to small, chemically synthesized organic molecules and encompasses the manufacture of both active pharmaceutical ingredients (APIs) and the subsequent drug product. Continuous drug product is currently used in approved processes. A few examples of production of APIs under current good manufacturing practice conditions using continuous processing steps have been published in the past five years, but they are lagging behind continuous drug product with respect to regulatory filings.
科研通智能强力驱动
Strongly Powered by AbleSci AI